GW’s focus is to bring novel prescription medicines to market which provide patients with serious conditions with valuable medicines which make a real difference to their quality of life. Through rapid cost-effective product development, addressing market needs, and establishing commercial partnerships, GW seeks to maximise the value of its products and shareholder returns.
GW’s strategy is to maintain a world leading position in the field of cannabinoid science and in the research, development and commercialisation of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates.
In seeking to implement this strategy, GW has developed an extensive international network of the most prominent scientists in the cannabinoid field and has also assembled a large in-house team with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. GW also holds controlled substance licences as well as GMP manufacturing licences for the manufacture of its prescription pharmaceutical products.
GW seeks to enter into licence agreements with major pharmaceutical companies with a view to those companies undertaking the sales and marketing of GW’s products. Under such agreements, GW tends to retain control over product development and also retains the manufacturing expertise for its products. GW supplies finished packaged and labelled product to its pharmaceutical partners for the purposes of commercial distribution and sale.
In addition to entering into commercial licence agreements with pharmaceutical companies, GW also undertakes research in collaboration with academic institutions and clinicians around the world in order to explore potential new applications of cannabinoids.